Shared Care: Infusion in the City — Monitoring Near Home

Yes. Shared care is a routine, workable arrangement: the infusion and the decisions stay with one specialist centre, while blood tests, clinical review and early symptom checks happen near your home. It works when it is written down, one oncologist stays responsible, and both teams hold the same plan.

The arrangement is old and unremarkable in other parts of medicine, and almost nobody describes it to a cancer family. What families are given instead is a distance and a schedule. They do the arithmetic — the bus, the day of lost earnings for whoever travels, sometimes a night’s stay, repeated every few weeks for months — and then either uproot themselves or quietly stop coming. A third option sits in between. It is worth asking for by name.

Immunotherapy suits it better than most treatments. The infusion itself is short and is given as day care at CION centres; people usually go home the same afternoon. The demanding part is the three weeks afterwards — the blood test that shows a thyroid or liver change before you feel it, the symptom somebody notices early, the phone call made on the right day. Very little of that needs a city. Almost all of it needs a system.

• One oncologist stays responsible for the whole course. Not two half-owners. One named medical oncologist prescribes, reviews and authorises every change, whichever building you happen to be sitting in that week.
• The plan is written down and both teams hold a copy. Drug, dose, interval, which blood panels, at what interval, and which results mean stop and call. A verbal understanding between two busy departments is not a shared-care plan.
• The local unit knows exactly when to stop and phone. The whole value of shared care is catching something early. That only happens if the local doctor has a written threshold and no hesitation about acting on it.
• You carry your own records. The treatment card and the reports travel with you to every visit, at both ends. If a doctor who has never met you sees you at night, that paper is what tells them to think of an immune side effect at all.

Shared care is not the same thing as moving your treatment. In shared care the specialist centre keeps the prescription and the responsibility; nothing is handed over. If you are relocating permanently, or changing centre for good, that is a different process with different paperwork — Transferring Immunotherapy Treatment to Another Centre sets out what has to move with you.

Most monitoring can happen near home. Pre-cycle blood tests, clinical review, and the first assessment of a new symptom are all local work. The eligibility decision, the prescription and the first cycles belong at the specialist centre. Response scans are coordinated at partner imaging centres, and can often be done close to you.

By one named oncologist, one written plan, and one record that travels with you. The specialist centre sets the drug, dose and interval, and the thresholds that stop a cycle. The local unit does the bloods and the review, sends results the same day, and calls before proceeding when anything crosses a threshold.

1. 1

   Name the responsible oncologist

   Ask for it in writing on the plan: who prescribes, who reviews, and who authorises a change. One name, not a department and not a rotation.

2. 2

   Get the plan written before anything moves

   Drug, dose, interval, cycles planned, which blood panels at what interval, and the results that mean stop and call. Both teams hold the same copy.

3. 3

   Agree the local unit’s part explicitly

   Which tests it will do, which it will not, what it does with an abnormal result, and how quickly it can see you if a symptom appears between cycles.

4. 4

   Fix how results travel, both ways

   Same-day reporting to the treating team by an agreed route, with a named person at each end responsible for reading them. Results nobody owns are results nobody reads.

5. 5

   Carry a treatment card to every visit

   Drug name, dose, cycle dates, the helpline number, and a line saying the patient is on immunotherapy. Both centres write on the same document.

6. 6

   Pre-agree the escalation route

   Which hospital admits you if you deteriorate near home, whether that arrangement is written, and who tells the specialist team, and when.

7. 7

   Fix the specialist review dates in advance

   A periodic in-person review at the specialist centre, scheduled at the start of the course rather than arranged after something has already gone wrong.

Steps two and five carry most of the weight, and both are paperwork. If getting a copy of your own reports is already difficult, shared care will not work, because the plan depends on documents moving faster than patients do — Getting Your Treatment Records and Reports covers what to ask for and how. If the specialist centre is far enough that even the periodic review is a burden, ask whether part of it can be done remotely: Online and Remote Second Opinions for Immunotherapy explains what can and cannot be settled without a physical visit.

The commonest failure is that both teams assume the other is watching. Shared care fails on communication, not on competence. Every prevention is administrative: one owner, one written plan, results routed the same day, thresholds agreed in advance, and a record you carry yourself rather than one that lives in a filing cabinet.

• Both teams assume the other is watching. The local unit believes the specialist is reviewing the results; the specialist believes the local doctor would have called. Prevention is a single written owner, named on the plan, and a review date that is already in the diary.
• An abnormal result sits in a local file. A rising liver enzyme or a drifting thyroid is often the first sign of an immune side effect, and it is useless if it is filed rather than read. Prevention is same-day routing to a named person, agreed at the start.
• An immune side effect is treated as an infection. Loose motions become food poisoning, breathlessness becomes a chest infection, exhaustion becomes weakness after treatment. Antibiotics are given, steroids are not, and days pass. Prevention is the treatment card in your hand and a local doctor who has been told, in writing, what to consider first.
• The plan changes verbally, and only one team hears it. A dose is held, an interval is stretched, a panel is added — and the other centre carries on with the old version. Prevention is that every change is reissued in writing to both teams and to you.
• Medicine is sourced outside the hospital pharmacy to save a trip. Counterfeit checkpoint inhibitors have been reported entering the Indian market. A cold-chain biologic bought off-bill cannot be traced, verified or returned, and the saving is never worth it. Prevention is that the drug is always procured through a hospital pharmacy with a batch record.

No. CION Cancer Clinics does not provide CAR-T or any other cell therapy, and does not stock CAR-T product, so there is nothing here to share. That treatment belongs at a licensed cell-therapy centre. If it is raised as an option for you, the correct next step is a referral to such a centre.

CAR-T is a different category of treatment from a checkpoint inhibitor infusion, and the gap is not one of degree. It needs apheresis to collect the patient’s own cells, a licensed facility to modify and grow them, conditioning treatment before they are returned, and a team that manages cytokine release syndrome and neurological toxicity in intensive care. Very few centres in India are set up for it, and the list changes.

• What CION can do. Explain what has been proposed, what the eligibility questions usually are, and help you understand where such a referral would go.
• What CION does not do. Administer, arrange, stock or supervise CAR-T or any other cell therapy. Nothing on this page should be read as an offer of it.
• What to be wary of. Any unit offering cell therapy alongside routine day care, or any clinic offering unproven immune infusions under a similar-sounding name.

Shared care rests on three practical things: records that actually move, a clear line between sharing care and transferring it, and a way to get a specialist view without another journey. These pages take each one in turn, alongside the hub that explains how the whole pathway fits together.

• Getting Your Treatment Records and Reports — what to ask for after every cycle, and what to do when a centre is slow to hand it over.
• Transferring Immunotherapy Treatment to Another Centre — how a permanent move differs from shared care, and what has to travel with you.
• Online and Remote Second Opinions for Immunotherapy — what can be settled remotely, and what still needs somebody in the room.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring and escalation fit together as one pathway.

One thing worth saying plainly. Shared care is a way to make treatment reachable, not a reason to start it. Not having immunotherapy at all is a legitimate option, and so is being treated somewhere other than here. If the treatment does not suit the situation, or if even a shared plan is out of reach for your family, that belongs in the conversation with your oncologist before the first cycle — not in a decision made quietly, halfway through.

Ask for a Shared-Care Plan in Writing

Bring your reports. We will set out the drug, the schedule, the monitoring and the escalation route in writing, so both centres can be held to the same plan.